From Surf Wiki (app.surf) — the open knowledge base
DOTFE
| Column 1 |
|---|
| 4-(2,2,2-Trifluoroethyl)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2,2,2-trifluoroethyl)amphetamine |
| .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}None |
| IUPAC name |
| 1-[2,5-dimethoxy-4-(2,2,2-trifluoroethyl)phenyl]propan-2-amine |
| 170143488 |
| C13H18F3NO2 |
| 277.287 g·mol−1 |
| Interactive image |
| SMILES |
| COc1cc(CC(F)(F)F)c(cc1CC(N)C)OC |
| InChI |
| InChI=1S/C13H18F3NO2/c1-8(17)4-9-5-12(19-3)10(6-11(9)18-2)7-13(14,15)16/h5-6,8H,4,7,17H2,1-3H3Key:OZFGHDLWUVVAPY-UHFFFAOYSA-N |
DOTFE, also known as 4-(2,2,2-trifluoroethyl)-2,5-dimethoxyamphetamine, is a drug of the phenethylamine, amphetamine, and DOx families. It is a close analogue of known psychedelics like the DOx psychedelic DOTFM and the 2C psychedelics 2C-TFE and 2C-TFM. The drug was predicted to bind to the serotonin 5-HT2A receptor, with a predicted affinity (Ki) of 50 nM. It was inactive in humans at doses of up to 3 mg, but higher doses were not assessed. DOTFE is expected to be a potent psychedelic at active doses. It was first described in the scientific literature by at least 1999. DOTFE was evaluated in humans by Daniel Trachsel, with these reports published in 2012 and 2013.
-
DOx (psychedelics)
-
DOTFE - Isomer Design
Ask Mako anything about DOTFE — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report